Male patient talking with female physician

GIVE HYPERTENSION PATIENTS A NEW OPTION

HOW DOES RDN HELP REDUCE HIGH BLOOD PRESSURE?

When overactive nerves cause higher sympathetic activity, it can lead to hypertension for many patients. The Medtronic Renal Denervation (RDN) procedure ablates these nerves to reduce sympathetic activity in the renal arteries and lower blood pressure.

EXPLORE RDN
Medtronic clinician who focuses on hypertension (HTN) management and high blood pressure (HBP) treatments.

IS RDN RIGHT FOR YOUR PATIENTS?

Review the European Society of Cardiology (ESC) guidelines for Medtronic renal denervation patients and other resources to determine which of your patients may benefit from RDN.

VIEW PATIENT SELECTION CRITERIA
Play Video This will play a video - Male Doctor Talking to Camera

Dr. Kandzari presents the SPYRAL HTN-ON MED Trial results

WELL TESTED WELL PROVEN

REVIEW CLINICAL DATA

We can lower blood pressure with RDN.

Dr. Michael Burnier, Nephrologist & Hypertension expert

RAISE

EXPECTATIONS

LOWER BLOOD

PRESSURE

EXPLORE PRODUCTS
Symplicity SPYRAL Catheter

WANT TO KNOW MORE ABOUT RDN?

CONTACT US
Play Video This will play a video - Still image of video

Hypertension affects 1.13 billion people worldwide1

1 IN 4 MEN

AND

1 IN 5 WOMEN

WORLDWIDE HAS

HYPERTENSION<sup>2,3,4</sup>

Play Video This will play a video - Still image of video

Uncontrolled hypertension dramatically increases the risk of heart attack, heart failure, stroke, and kidney failure 4,5,6,7

ADULTS WITH HYPERTENSION SPEND 3.2X MORE ON MEDICAL CARE THAN THOSE WITHOUT HYPERTENSION8

Play Video This will play a video - Still image of video

10% of global healthcare spending is related to hypertension9

EXPLORE RDN FURTHER

Get the latest news about RDN and see if there is an upcoming event near you.

VISIT NEWS AND EVENTS
1

World Health Organization. Hypertension Fact Sheet. September 2019. Available at: https://www.who.int/news-room/fact-sheets/detail/hypertension. Accessed January 24, 2020.

2

 Ikeda N, Sapienza D, Guerrero R, et al. Control of hypertension with medication: a comparative analysis of national surveys in 20 countries. Bull World Health Organ. 2014;92:10–19C.

3

Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005:365:217-223.

4

CDC. Vital Signs: Awareness and Treatment of Uncontrolled Hypertension Among Adults — United States, 2003-2010. Morbidity and MMWR. September 7, 2012;61(35):703-709. Available at: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6135a3.htm. Accessed May 22, 2019.

5

Welton PK, Carey RM, Aronow WS, et al. 2017 High Blood Pressure Clinical Practice Guideline Hypertension. 2018;71:1269-1324.

6

WHO. The world health report 2002 — Reducing Risks, Promoting Healthy Life. Available at: http://www.who.int/whr/2002/en/. Accessed January 10, 2020.

7

Messerli FH, Williams B, Ritz E. Essential Hypertension. Lancet. 2007

8

HCCI research 2018.

9

WHL and ISH Hypertension Fact Sheet. Available at: http://ish-world.com/news/a/WHL-and-ISH-Hypertension-Fact-Sheet. Accessed January 22, 2020.

All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.  For distribution only in markets where the Symplicity Spyral™ multi-electrode renal denervation catheter and Symplicity G3™ renal denervation RF generator have been approved. Not for distribution in the USA, Japan or France.